前列腺癌中[68Ga]Ga-PSMA-11 PET/CT与循环肿瘤DNA的发现率及预后效用比较——一项横断面研究
纳入130例确诊前列腺癌男性(70.5±8.0岁),于2019年3月至2021年8月行[68Ga]Ga-PSMA-11 PET/CT(184.8±19.7 MBq)并采集血浆行全基因组ctDNA分析。PSMA PET发现率按去势状态和PSA区间有显著差异(P=0.013,P<0.001),ctDNA发现率无差异(P=0.311,P=0.123);PSMA-TV和ctDNA水平均与生存独立相关。
要点
- PSMA PET发现率按去势状态和PSA区间差异显著,ctDNA发现率无显著差异。
- ctDNA浓度与PSMA-TV在全体和去势抵抗患者中显著相关,激素敏感患者中不显著。
- PSMA-TV和ctDNA水平在Logrank和多因素Cox回归中均与生存结局相关。
核心结论
- 作者认为PSMA PET显像在检测前列腺癌全疾病谱方面优于ctDNA分析,同时两种方法对生存结局均具有独立的高度预后价值。
研究设计与样本
- 横断面研究,纳入130例确诊前列腺癌男性(70.5±8.0岁),于2019年3月至2021年8月行[68Ga]Ga-PSMA-11 PET/CT(184.8±19.7 MBq)并采集血浆。
- 血浆提取游离DNA行基于全基因组的ctDNA分析,勾画PSMA阳性肿瘤病灶并提取定量参数。
- 比较ctDNA与PSMA PET/CT的发现率,并评估对总生存(OS)的预后价值。
主要发现
- PSMA PET发现率按去势状态和PSA区间比较差异显著(P=0.013,P<0.001),ctDNA发现率按去势状态和PSA区间比较无显著差异(P=0.311,P=0.123)。
- ctDNA发现率在局限性疾病与转移性疾病之间差异显著(P=0.013)。
- ctDNA浓度与PSMA阳性肿瘤体积(PSMA-TV)在全体患者中显著相关(r=0.42,P<0.001),在去势抵抗患者中显著相关(r=0.65,P<0.001),在激素敏感患者中无显著相关(r=0.15,P=0.249)。
- PSMA-TV和ctDNA水平与生存结局相关:Logrank分析P<0.0001、P<0.0001,多因素Cox回归分析P=0.0023、P<0.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Circulating-tumor DNA (ctDNA) and prostate-specific membrane antigen (PSMA) ligand positron-emission tomography (PET) enable minimal-invasive prostate cancer (PCa) detection and survival prognostication. The present study aims to compare their tumor discovery abilities and prognostic values. METHODS: One hundred thirty men with confirmed PCa (70.5 ± 8.0 years) who underwent [68Ga]Ga-PSMA-11 PET/CT (184.8 ± 19.7 MBq) imaging and plasma sample collection (March 2019-August 2021) were included. Plasma-extracted cell-free DNA was subjected to whole-genome-based ctDNA analysis. PSMA-positive tumor lesions were delineated and their quantitative parameters extracted. ctDNA and PSMA PET/CT discovery rates were compared, and the prognostic value for overall survival (OS) was evaluated. RESULTS: PSMA PET discovery rates according to castration status and PSA ranges did differ significantly (P = 0.013, P < 0.001), while ctDNA discovery rates did not (P = 0.311, P = 0.123). ctDNA discovery rates differed between localized and metastatic disease (P = 0.013). Correlations between ctDNA concentrations and PSMA-positive tumor volume (PSMA-TV) were significant in all (r = 0.42, P < 0.001) and castration-resistant (r = 0.65, P < 0.001), however not in hormone-sensitive patients (r = 0.15, P = 0.249). PSMA-TV and ctDNA levels were associated with survival outcomes in the Logrank (P < 0.0001, P < 0.0001) and multivariate Cox regression analysis (P = 0.0023, P < 0.0001). CONCLUSION: These findings suggest that PSMA PET imaging outperforms ctDNA analysis in detecting prostate cancer across the whole spectrum of disease, while both modalities are independently highly prognostic for survival outcomes.
引用
- Kluge K, Einspieler H, Haberl D, et al. Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional study. Eur J Nucl Med Mol Imaging. 2024. PMID: 38693454. doi:10.1007/s00259-024-06698-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。